Juan Pablo Sade
A5050957629- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Bladder and Urothelial Cancer Treatments
- Radiopharmaceutical Chemistry and Applications
- Cancer Immunotherapy and Biomarkers
- Cancer, Lipids, and Metabolism
- Urinary and Genital Oncology Studies
- PARP inhibition in cancer therapy
- Renal cell carcinoma treatment
- Bone health and treatments
- Medical Imaging Techniques and Applications
- Neuroblastoma Research and Treatments
- COVID-19 and healthcare impacts
- Endometrial and Cervical Cancer Treatments
- Artificial Intelligence in Healthcare
- Cancer Genomics and Diagnostics
- Testicular diseases and treatments
- Cancer Diagnosis and Treatment
- Genital Health and Disease
- Multiple Myeloma Research and Treatments
- Hormonal and reproductive studies
- Allergic Rhinitis and Sensitization
- Time Series Analysis and Forecasting
- Esophageal Cancer Research and Treatment
- Urologic and reproductive health conditions
Instituto Alexander Fleming
2016-2025
Fundación para la Investigación, Docencia y Prevención del Cáncer
2024
Yıldız Technical University
2024
Icahn School of Medicine at Mount Sinai
2023
Dana-Farber Cancer Institute
2023
Mount Vernon Cancer Centre
2022
Institute of Oncology Research
2022
University College London
2022
The Royal Free Hospital
2022
Ospedale Santa Chiara
2022
Innovations in treatments, imaging, and molecular characterisation advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform clinical practice. The Advanced Prostate Cancer Consensus Conference (APCCC) 2019 addressed some these topics supplement guidelines based on level 1 evidence.To present the results from APCCC 2019.Similar prior conferences, experts identified 10 important areas controversy regarding cancer:...
No new agent has improved overall survival in patients with unresectable or metastatic urothelial carcinoma when added to first-line cisplatin-based chemotherapy.In this phase 3, multinational, open-label trial, we randomly assigned previously untreated either receive intravenous nivolumab (at a dose of 360 mg) plus gemcitabine-cisplatin (nivolumab combination) every 3 weeks for up six cycles, followed by 480 4 maximum 2 years, alone cycles. The primary outcomes were and progression-free...
Innovations in imaging and molecular characterisation the evolution of new therapies have improved outcomes advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety clinical topics that greatly impact daily practice. To supplement evidence-based guidelines, 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) surveyed experts about key dilemmas management.To present consensus voting results for select questions from APCCC 2022.Before conference,...
There is an unmet need for therapeutic options that prolong survival patients with heavily pretreated, metastatic castration-resistant prostate cancer (mCRPC). The phase III, open-label KEYLYNK-010 study evaluated pembrolizumab plus olaparib versus a next-generation hormonal agent (NHA) biomarker-unselected, previously treated mCRPC.
Innovations have improved outcomes in advanced prostate cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that greatly impact daily practice. The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) surveyed experts key questions clinical management order supplement evidence-based guidelines. Here present voting results for from APCCC 2024.
4509 Background: In the CheckMate 901 trial, combination nivolumab (NIVO) + gemcitabine-cisplatin (GC) demonstrated significant improvements in overall survival (OS) and progression-free (PFS) with compelling objective response rates (ORR; 57.6% NIVO+GC vs 43.1% GC alone) deep, durable complete responses (CR; 21.7% 11.8% patients (pts) previously untreated unresectable or metastatic urothelial carcinoma (mUC). Lymph node (LN)-only disease is a favorable prognostic factor pts mUC subset of...
438 Background: In the randomized, double-blind, phase 3 COSMIC-313 study (NCT03937219), C+N+I significantly improved PFS compared with N+I in first-line intermediate or poor risk aRCC, meeting primary endpoint (Choueiri et al. N Engl J Med 2023). Here, we present secondary of OS, updated efficacy and safety results, biomarker analyses. Methods: Patients (pts) previously untreated, IMDC aRCC were randomized to receive C 40 mg QD placebo (P). Both groups received (3 mg/kg IV Q3W) + I (1 for 4...
Radium-223, a targeted alpha therapy, is approved to treat bone-dominant metastatic castration-resistant prostate cancer (mCRPC), based on significantly prolonged overall survival versus placebo and favourable safety profile in the phase 3 ALSYMPCA study. was conducted when few other treatment options were available, prospectively collected data are limited use of radium-223 current mCRPC landscape. We sought understand long-term patterns men who received real-world clinical...
Abstract Background Immune checkpoint inhibitors have changed previous treatment paradigm of advanced urothelial carcinoma (UC). The ARON-2 study (NCT05290038) aimed to assess the real-world effectiveness pembrolizumab in patients recurred or progressed after platinum-based chemotherapy. Patients and Methods Medical records with documented metastatic UC treated by as second-line therapy were retrospectively collected from 88 institutions 23 countries. assessed for overall survival (OS),...
Plain Language SummaryWhat is this summary about?This article describes the results of a clinical research study called 'CheckMate 901',which was published in The New England Journal Medicine. CheckMate 901 that looked at specific type cancer urothelial cancer, which impacts parts urinary system. Participants had either unresectable (meaning it cannot be removed by surgery) or metastatic(where has spread from system to other body).Unresectable metastatic normally treated with...
502 Background: Deferred cytoreductive nephrectomy (dCN) is an emerging, strategy in the management of metastatic renal cell carcinoma (mRCC), applied selectively to patients who demonstrate a favorable response initial systemic therapy. This study aimed assess clinical impact dCN within context sequential treatment management. Methods: A multi-institutional retrospective evaluation. The descriptive analysis was performed examine demographic and characteristics. Progression-free survival...
Gender- and sex-based disparities in response to immune-checkpoint inhibitors (ICI) has been reported a variety of tumor types. Women have different anatomy with recurrent urinary tract infections, sex hormonal profile, intrinsic differences local systemic immune systems urobiome composition. Existing literature data pan-cancer context reveal contradictory results, real-world evidence urothelial carcinoma (UC) is lacking. This was real-world, multicenter, international, observational study...
OBJECTIVES/PROBLEM: To determine the sinonasal effect of aspirin salicylic acid (ASA) desensitization in patients with nasal polyps, asthma and intolerance (ASA triad). METHODS OF STUDY: Patients ASA triad were recruited from outpatient otolaryngology clinic. They underwent a program (2005 - 2008) prospective assessment subjective objective responses. Incremental doses given to reach target 625 mg twice daily during period 3 5 days. A maintenance dose was then for study period. The also...
Prostate cancer (PCa) is the most frequent tumor among Latin American (LATAM) men. The incidence of de novo metastatic PCa higher in LATAM than other parts world, and demographic changes region have increased disease burden. However, region-specific information regarding prevalence, progression, treatment effectiveness not currently available for nonmetastatic, castration-resistant (nmCRPC). Nonmetastatic, a heterogeneous with varying potential to develop metastasis limited treatments...
To present a summary of the recommendations for treatment and follow-up metastatic castration-resistant prostate cancer (mCRPC) as acquired through questionnaire administered to 99 physicians working in field developing countries who attended Prostate Cancer Consensus Conference Developing Countries.
Patients with advanced prostate cancer (APC) may be at greater risk for severe illness, hospitalisation, or death from coronavirus disease 2019 (COVID-19) due to male gender, older age, potential immunosuppressive treatments, comorbidities. Thus, the optimal management of APC patients during COVID-19 pandemic is complex. In October 2021, Advanced Prostate Cancer Consensus Conference (APCCC) 73 voting members panel discussed and voted on 13 questions this topic that could help clinicians make...
PURPOSE This study aims to describe genomic characteristics of patients with metastatic prostate cancer (mPC). PATIENTS AND METHODS is a retrospective, multicenter cohort mPC and reports on testing. Patients were included from 12 academic centers in five countries. RESULTS A total 349 PC this study. Most (209, 59.9%) de novo metastatic. Genomic analysis was performed 233 (66.6%) the castration-resistant (mCRPC) setting, only 115 (32.8%) had tumor evaluation hormone sensitive scenario. The...